Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.B1 - hyaluronan-binding serine protease

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
Hyaluronan-binding protein 2 (HABP2) gene variation in women with recurrent miscarriage.
Abortion, Spontaneous
Hyaluronan-binding protein 2 (HABP2) gene variation in women with recurrent miscarriage.
Acute Coronary Syndrome
Circulating Factor VII Activating Protease (FSAP) Is Associated With Clinical Outcome in Acute Coronary Syndrome.
Acute Kidney Injury
The delayed administration of pHBSP, a novel non-erythropoietic analogue of erythropoietin, attenuates acute kidney injury.
Acute Lung Injury
Hyaluronic Acid binding protein 2 is a novel regulator of vascular integrity.
Adenocarcinoma
Novel candidate tumor marker genes for lung adenocarcinoma.
Adenocarcinoma of Lung
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.
Atherosclerosis
Factor VII-activating protease (FSAP): vascular functions and role in atherosclerosis.
Protease activated receptors (PAR)-1 and -2 mediate cellular effects of factor VII activating protease (FSAP).
Qualitative detection of the Marburg I alloenzyme of factor VII-activating protease by an immunoassay and its comparison to PCR testing.
The Factor VII-activating Protease (FSAP) Enhances the Activity of Bone Morphogenetic Protein-2 (BMP-2).
Atrial Fibrillation
Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study.
Brain Injuries
Neuroprotection with an Erythropoietin Mimetic Peptide (pHBSP) in a Model of Mild Traumatic Brain Injury Complicated by Hemorrhagic Shock.
Breast Neoplasms
Common genetic variation and novel loci associated with volumetric mammographic density.
HABP2 p.G534E variant in patients with family history of thyroid and breast cancer.
Carcinoma
Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma.
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.
Novel candidate tumor marker genes for lung adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.
Carcinoma, Renal Cell
Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma.
Carcinoma, Squamous Cell
Novel candidate tumor marker genes for lung adenocarcinoma.
Cardiovascular Diseases
Factor VII-activating protease: sex-related association with coronary artery calcification.
Structure-function analysis of factor VII activating protease (FSAP): sequence determinants for heparin binding and cellular functions.
The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation.
Carotid Stenosis
Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism.
Qualitative detection of the Marburg I alloenzyme of factor VII-activating protease by an immunoassay and its comparison to PCR testing.
Tests for the measurement of factor VII-activating protease (FSAP) activity and antigen levels in citrated plasma, their correlation to PCR testing, and utility for the detection of the Marburg I-polymorphism of FSAP.
The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation.
Cerebral Infarction
[Marburg I polymorphism of Factor VII-activating protease and cerebral infarction]
Coronary Artery Disease
Expression of the Marburg I Single Nucleotide Polymorphism (MI-SNP) and the Marburg II Single Nucleotide Polymorphism (MII-SNP) of the Factor VII-Activating Protease (FSAP) Gene and Risk of Coronary Artery Disease (CAD): A Pilot Study in a Single Population.
Endometrial Neoplasms
Diagnostic and prognostic value of HABP2 as a novel biomarker for endometrial cancer.
endopeptidase la deficiency
Factor VII-activating protease deficiency promotes neointima formation by enhancing leukocyte accumulation.
Hamartoma Syndrome, Multiple
Familial non-medullary thyroid cancer: unraveling the genetic maze.
Hepatitis C
The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB.
hyaluronan-binding serine protease deficiency
Factor VII-activating protease deficiency promotes neointima formation by enhancing leukocyte accumulation.
Hypotension
Neuroprotection with an Erythropoietin Mimetic Peptide (pHBSP) in a Model of Mild Traumatic Brain Injury Complicated by Hemorrhagic Shock.
Infections
The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB.
Infertility
Variation in Hyaluronan-Binding Protein 2 (HABP2) Promoter Region is Associated With Unexplained Female Infertility.
Insulin Resistance
Nonerythropoietic Erythropoietin-Derived Peptide Suppresses Adipogenesis, Inflammation, Obesity and Insulin Resistance.
Ischemic Stroke
Association of GWAS-Reported Variant rs11196288 near HABP2 with Ischemic Stroke in Chinese Han Population.
Deficiency of Factor VII activating protease alters the outcome of ischemic stroke in mice.
Factor seven activating protease (FSAP) predicts response to intravenous thrombolysis in acute ischemic stroke.
Liver Cirrhosis
Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men.
Factor VII activating protease (FSAP): A novel protective factor in liver fibrosis.
Structure-function analysis of factor VII activating protease (FSAP): sequence determinants for heparin binding and cellular functions.
The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB.
Transforming growth factor-beta (TGF-?) inhibits the expression of factor VII activating protease (FSAP) in hepatocytes.
Lung Injury
Changes in factor VII-activating protease in a bleomycin-induced lung injury rat model and its influence on human pulmonary fibroblasts in vitro.
Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases.
Erythropoietin-Derived Peptide Protects Against Acute Lung Injury After Rat Traumatic Brain Injury.
Lung Neoplasms
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.
Neoplasm Metastasis
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.
Neoplasm, Residual
Diagnostic and prognostic value of HABP2 as a novel biomarker for endometrial cancer.
Neoplasms
Common genetic variation and novel loci associated with volumetric mammographic density.
Diagnostic and prognostic value of HABP2 as a novel biomarker for endometrial cancer.
Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.
HABP2 G534E Variant in Papillary Thyroid Carcinoma.
HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.
HABP2 p.G534E variant in patients with family history of thyroid and breast cancer.
Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of "thyroid-checked" controls.
Pitfalls of exome sequencing: a case study of the attribution of HABP2 rs7080536 in familial non-medullary thyroid cancer.
Protease activated receptors (PAR)-1 and -2 mediate cellular effects of factor VII activating protease (FSAP).
Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review.
Obesity
Nonerythropoietic Erythropoietin-Derived Peptide Suppresses Adipogenesis, Inflammation, Obesity and Insulin Resistance.
Respiratory Distress Syndrome
Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases.
Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome.
Raised protein levels and altered cellular expression of factor VII activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS).
Sepsis
Complexes of factor VII-activating protease with plasminogen activator inhibitor-1 in human sepsis.
Stroke
Factor seven activating protease (FSAP) predicts response to intravenous thrombolysis in acute ischemic stroke.
Factor VII activating protease (FSAP) influences vascular remodeling in the mouse hind limb ischemia model.
Factor VII activating protease (FSAP) regulates the expression of inflammatory genes in vascular smooth muscle and endothelial cells.
Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and Mortality.
Genome-Wide Association Analysis of Young-Onset Stroke Identifies a Locus on Chromosome 10q25 Near HABP2.
Protease activated receptors (PAR)-1 and -2 mediate cellular effects of factor VII activating protease (FSAP).
Thromboembolism
Qualitative detection of the Marburg I alloenzyme of factor VII-activating protease by an immunoassay and its comparison to PCR testing.
Thrombophilia
Direct chromogenic substrate immuno-capture activity assay for testing of factor VII-activating protease.
Qualitative detection of the Marburg I alloenzyme of factor VII-activating protease by an immunoassay and its comparison to PCR testing.
Thrombosis
Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP).
Factor VII activating protease (FSAP) influences vascular remodeling in the mouse hind limb ischemia model.
Factor VII-activating protease deficiency promotes neointima formation by enhancing leukocyte accumulation.
Protease activated receptors (PAR)-1 and -2 mediate cellular effects of factor VII activating protease (FSAP).
Thyroid Cancer, Papillary
Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.
Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.
HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
HABP2 G534E Variant in Papillary Thyroid Carcinoma.
HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
HABP2 p.G534E variant in patients with family history of thyroid and breast cancer.
Letter regarding the article: "Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of "thyroid-checked" controls" by Kern et al.
Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of "thyroid-checked" controls.
RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review.
The G534E variant in HABP2 is not associated with increased risk of familial nonmedullary thyroid cancer in Brazilian Kindreds.
The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish population.
Thyroid Neoplasms
G534E Variant in HABP2 and Nonmedullary Thyroid Cancer.
Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.
HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series.
HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
HABP2 in Familial Non-medullary Thyroid Cancer: Will the Real Mutation Please Stand Up?
HABP2 Mutation and Nonmedullary Thyroid Cancer.
Lac color inhibits development of rat thyroid carcinomas through targeting activation of plasma hyaluronan-binding protein.
Letter regarding the article: "Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of "thyroid-checked" controls" by Kern et al.
Pitfalls of exome sequencing: a case study of the attribution of HABP2 rs7080536 in familial non-medullary thyroid cancer.
RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review.
The G534E variant in HABP2 is not associated with increased risk of familial nonmedullary thyroid cancer in Brazilian Kindreds.
The HABP2 G534E polymorphism does not increase nonmedullary thyroid cancer risk in Hispanics.
The HABP2 G534E variant is an unlikely cause of familial non-medullary thyroid cancer.
The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish population.
Vascular Diseases
Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and Mortality.
Vascular System Injuries
Factor VII activating protease (FSAP) regulates the expression of inflammatory genes in vascular smooth muscle and endothelial cells.
Venous Thromboembolism
Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism.
Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism.
Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism.
Tests for the measurement of factor VII-activating protease (FSAP) activity and antigen levels in citrated plasma, their correlation to PCR testing, and utility for the detection of the Marburg I-polymorphism of FSAP.
The Marburg I polymorphism of factor VII-activating protease and the risk of venous thromboembolism.
Venous Thrombosis
Factor VII-activating protease in patients with acute deep venous thrombosis.
The G534E-polymorphism of the gene encoding the Factor VII-activating protease is a risk factor for venous thrombosis and recurrent events.
The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis.